Royalty Pharma’s EVP Unwinds 20,000 Shares Amid Teva Deal, Raising Shareholder Concerns over Insider Selling Trend
Royalty Pharma insiders sell shares at flat prices amid new Teva deal – understand the structured sales, valuation, and long‑term royalty upside for investors.
3 minutes to read